Clinical trial
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir…
NCT00082394 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00082394 |
|---|---|
| Title | A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV |
| Official title | A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Infection, Human Immunodeficiency Virus I, HIV Infection |
| Intervention type | Drug |
| Interventions | Trizivir, atazanavir, Combivir |
| Start date | Apr 26, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | May 10, 2004 |
| Last update posted | May 24, 2017 |
| Countries | Mexico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: